Skip Nav Destination


Editors-In-Chief
Elaine R. Mardis, PhD
Nationwide Children's Hospital
The Ohio State University
Lillian L. Siu, MD
Princess Margaret Cancer Centre
University of Toronto
Editors-In-Chief

Elaine R. Mardis, PhD
Nationwide Children's Hospital
The Ohio State University
Nationwide Children's Hospital
The Ohio State University

Lillian L. Siu, MD
Princess Margaret Cancer Centre
University of Toronto
Princess Margaret Cancer Centre
University of Toronto
Editors' Corner
Editorial: Reflecting on Three Transformative Years of CRC
As we celebrate the third anniversary of Cancer Research Communications (CRC), we reflect on the remarkable journey we have undertaken since assuming the roles of co-Editors-in-Chief...(read more)
Editors’ Corner Archive
Journal Sections
Molecular and Cellular Biology
Imade Williams, Matthew O’Malley et al.
Nathan M. Jameson, Daehwan Kim et al.
Anne Nathalie Longakit, Oscar Urtatiz et al.
Tumor Biology
Chengsheng Wu, Tami Von Schalscha et al.
Nikhil Cherian Kurian, Peter H. Gann et al.
Megumi Kuronishi, Yoichi Ozawa et al.
Immuno-oncology
Eva Munoz-Couselo, Ainara Soria Rivas et al.
Emerging Technologies and Data Science
Elizabeth S. McDonald, Tien-Chi Pan et al.
Anne Nathalie Longakit, Oscar Urtatiz et al.
Chengsheng Wu, Tami Von Schalscha et al.
Therapeutic Research and Development
Imade Williams, Matthew O’Malley et al.
Nathan M. Jameson, Daehwan Kim et al.
Precision Medicine and Biomarkers
Imade Williams, Matthew O’Malley et al.
Elizabeth S. McDonald, Tien-Chi Pan et al.
John R. Lozada, Andrew Elliott et al.
Clinical Research and Trials
Elizabeth S. McDonald, Tien-Chi Pan et al.
Eva Munoz-Couselo, Ainara Soria Rivas et al.
Epidemiology and Prevention
Alexandra Lukey, Ramlogan Sowamber et al.
Saurabh Mandal, Emily A. Teslow et al.
Health Disparities and Outcomes Research
William O. Carson, Alyssa Little et al.
Gopika SenthilKumar, Aronne M. Schottstaedt et al.
Katherine Ross-Driscoll, Arrey-Takor Ayuk-Arrey et al.
Trending - Altmetric
Read the article titled, Phase 1b study of immunocytokine simlukafusp alfa (FAP-IL2v) combined with pembrolizumab for treatment of advanced and/or metastatic melanoma.
Last mentioned on Thursday February 6 2025
Read the article titled, The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models.
Last mentioned on Thursday February 6 2025